The FASTinov

FASTinov is a R&D intensive Startup with a patented disruptive technology to perform fast and reliable antimicrobial susceptibility tests in acute care settings. Context : The global emergence and spread of antimicrobial resistance is a major medical and economic problem . When an infection is diagnosed, the physician is required to start an empiric larg e spectrum therapy, since current comprehensive and proven susceptibility profile methods require, at least, 48h. FASTinov approach : In order to support clinical decisions with a fast turnaround time, FASTinov offers a unique time-saving and comprehensive solution starting directly from positive blood cultures. FASTinov innovative approach allows for the determination of the susceptibility phenotype in 2 hours, compared with +48 hours needed for current standard methods. Disruptive Technology : "FAST " patented methodology (Flow Cytometry Antimicrobial Susceptibility Test) fills a gap in existing AST methods: microbial cells can now be discriminated in terms of S usceptible vs R esistant phenotypes, independent of growth. FAST methodology provides the susceptibility profile in clinically useful time and clarifies the main resistance mechanism involved. All-in-one kit : Sample prep, probes, antibiotics, reagents and a dedicated analytical software package developed by FASTinov allowing the test to become more automatized and operator independent and provides clear guidance for the best use of antibiotics based on established international recommendations from EUCAST and CLSI. Value Proposition : By providing a fast susceptibility profile and guidance support for clinical prescriptions and decisions in acute care settings, FASTinov strongly contributes to the reduction of: i ) medication costs; ii) clinical therapeutical failure; iii) diagnostic and hospitalization costs; iv) antimicrobial resistance; v) spread of multi-resistant strains. FASTinov patented methodology is based on an early detection of microbial cell lesions or metabolic changes, relying on fluorochromes that target specific changes and make this identifiable through flow cytometer analysis.